Silver Book Fact

Donepezil, a cholinesterase inhibitor, has been found to slow progression of Alzheimer’s disease in its early stages, delaying the need for nursing home care by an average of 30 months.

Provenzano, George, Sandeep Duttagupta, Thomas McRae, et al. Delays in Nursing Home Placement for Patients with Alzheimer s Disease Associated with Donepezil May Have Care Cost Savings Implications. Value in Health. 2001; 4(2): 158. https://www.valueinhealthjournal.com/article/S1098-3015(11)71392-4/abstract

Reference

Title
Delays in Nursing Home Placement for Patients with Alzheimer s Disease Associated with Donepezil May Have Care Cost Savings Implications
Publication
Value in Health
Publication Date
2001
Authors
Provenzano, George, Sandeep Duttagupta, Thomas McRae, et al
Volume & Issue
Volume 4, Issue 2
Pages
158
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • An Alzheimer’s disease research study showed that billions of dollars could be saved if physicians could intervene before someone becomes symptomatic. This positive net savings occurred with both drug treatment…  
  • “If you or a loved one started exhibiting symptoms of Alzheimer’s disease 12 years ago, there were no medicines for you to take. All you could do was hope–that…  
  • According to one Parkinson’s expert, a 10% slowing of Parkinson’s disease progression would save $327 million per year.  
  • An Alzheimer’s treatment breakthrough that slowed disease progression and began to show effects in 2015, would reduce Medicaid costs for people with the disease by $62 billion–from the expected $178…  
  • Impact of a 5-Year Delay in Onset on Costs, Americans Age 65 and Older with Alzhemier’s Disease, 2010-2050